🚨 Breaking News: Ipsen Achieves its Record-High S&P Global Rating! 🚨 We’re thrilled to announce that Ipsen’s rating in the 2024 S&P Global Corporate Sustainability Assessment (CSA) has soared to an all-time high of 61 as of 19 September 2024, placing us in the 94th percentile of our industry! 🌍🚀 This reflects our unwavering commitment to sustainability, transparency, and continuous improvement. With an 87% disclosure rate, we’re leading the way in responsible business practices. 🚀 Together, as #GenerationIpsen, we’re shaping a sustainable future, one milestone at a time. 🌱 Learn more: https://lnkd.in/enpzrq_d #Sustainability #ESG #CorporateResponsibility #BreakingNews
À propos
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com. Pauta exclusiva para México: Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO.
- Site web
-
http://www.ipsen.com
Lien externe pour Ipsen
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- 5 001-10 000 employés
- Siège social
- Boulogne Billancourt
- Type
- Société cotée en bourse
- Domaines
- Pharmaceuticals, Specialty care: oncology, neuroscience, endocrinology, Research: peptides, toxins et Primary Care
Lieux
Employés chez Ipsen
Nouvelles
-
As Dystonia Awareness Month draws to a close, this new short film by ERN-RND, European Reference Network for Rare Neurological Diseases is a powerful reminder of the challenges faced by people living with this debilitating neurological condition at every stage of disease progression. We are proud that the film was inspired by the patient persona of ‘Lily’, which was created as part of the Cervical Dystonia Patient Experience Map Dystonia Europe published in collaboration with Ipsen: https://lnkd.in/e9C__5Hd
ERN-RND Scientific Theatre: Dystonia - Lily's Journey
https://www.youtube.com/
-
#Ipsen announces the European Commission has approved a new treatment option to manage the intolerable itch experienced by patients from six months old who are living with Alagille Syndrome #Pharma #Investors #Media #RareDiseases #ALGS Learn more: https://lnkd.in/eww8SNbd
-
🌍 Ipsen’s Commitment to Zero Emissions 🌍 At Ipsen, we are taking decisive action to mitigate climate change and achieve net-zero emissions. Our Generation Ipsen strategy highlights our ongoing efforts and commitment to a sustainable future. Read more here: https://lnkd.in/ez3ZrZvd #ZeroEmissionDay #Sustainability #ClimateAction #NetZero #Ipsen #GenerationIpsen
-
The European Commission has given approval for a new treatment for the rare liver disease, primary biliary cholangitis (#PBC). With many patients being unresponsive to the current medicines it is great to offer a new treatment choice. #Ipsen #Pharma #RareDiseases #PrimaryBiliaryCholangitis
-
The European Commission has approved a new treatment for primary biliary cholangitis #PBC. It is the first new medicine for this rare cholestatic liver disease for nearly a decade. #Ipsen #Pharma #Investors #Media #RareDiseases #PrimaryBiliaryCholangitis Learn more: https://lnkd.in/ezcBZQt9
-
With new breakthroughs being unveiled, we’re thrilled to see cutting-edge new science first-hand at #ESMO24 in Barcelona. From delivering new innovations today and accelerating exciting new modalities for tomorrow, we’re pushing the boundaries of science for people living with cancer. Learn more: https://lnkd.in/eMpWrhrV
-
Sandra Silvestri, MD, PhD, Ipsen’s EVP and Chief Medical Officer is discussing the importance of collaboration in #PrimaryBiliaryCholangitis (PBC) this #PBCAwarenessMonth. Read her article here: https://lnkd.in/ewtbGPXM #LivingWithPBC #PatientCare
Executive Vice President & Chief Medical Officer, Head of Global Medical Affairs, Global Patient Safety and Global Patient Affairs, ExComm member @ Ipsen, Board Member @ Genfit
Living with #PrimaryBiliaryCholangits (PBC) significantly impacts quality of life for those living with the rare condition. This #PBCAwarenessMonth the @PBC Foundation is calling for #ProvideBetterCare, here at Ipsen we are throwing our support behind this campaign. Read more on this topic.
-
At Ipsen, we value innovation through diversity 💡. This year, we honor five para-athletes who, by overcoming barriers, inspire our pursuit of impactful excellence for a better and a healthier world 🌍 🏅🌟. Discover the inspiring journeys of Mathieu THOMAS and Gaëlle Edon 👇✨. #InnovationThroughDiversity #ParaAthletes #OvercomingBarriers #Inspiration #Excellence #SportsForAll #ChampionStories #DisabilityAwareness #InclusionMatters #IpsenValues
Pages similaires
Parcourir les offres d’emploi
Financement
Dernier round
Capital après introduction en Bourse29 134 597,00 $US